Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue.
Leuprolide acetate, a gonadotropin-releasing hormone analogue, produced a variety of beneficial therapeutic responses in five patients with ovarian carcinoma. Four patients had failed intensive chemotherapy with alkylating agents, cisplatin, and Adriamycin. All had one or more clinical conditions that precluded treatment with cytotoxic agents and characteristics associated with resistance to hormone therapy. Our findings support evaluation of expanded eligibility criteria for new hormonal therapy in cases of refractory ovarian carcinoma.
Bruckner
H W
HW
Department of Neoplastic Diseases, Mount Sinai School of Medicine, New York, NY 10029-6574.
Motwani
B T
BT
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006728:Hormones; D006801:Humans; D016729:Leuprolide; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010906:Pituitary Hormone-Releasing Hormones / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D006728:Hormones; D010906:Pituitary Hormone-Releasing Hormones; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide